Skip Navigation

DRUG RECORD

 

DIPYRIDAMOLE

OVERVIEW
Dipyridamole

 

Introduction

Dipyridamole is a vasodilator and inhibitor of platelet aggregation that is used to decrease the risk of thromboembolic complications and recurrence of stroke in patients known to have atherosclerotic cerebrovascular disease.  Dipyridamole is associated with a low rate of serum enzyme elevations during treatment, but has not been linked to instances of clinically apparent acute liver injury.

 

Background

Dipyridamole (dye' pir id' a mole) is a pyrimidine analogue that is used as an antiplatelet agent to decrease the risk of thromboembolic complications in patients at high risk, such as with a prosthetic heart value, with hypercoagulable states and with a history of arterial thromboses (heart attack, stroke).  Dipyridamole is usually given in combination with other anticoagulants or antiplatelet agents such as warfarin or aspirin.  Dipyridamole was approved for use in the United States in 1961 as an adjunct to coumarin anticoagulants in prevention of thromboembolic complications of cardiac valve replacements.  Dipyridamole is available in tablets of 25, 50 and 75 mg in generic forms and under the trade name Persantine.  It is also available in fixed combinations with aspirin under the name Aggrenox as prophylaxis to reduce the risk of stroke in patients with previous history of ischemic stroke or transient ischemic attacks.  The typical recommended dose varies by indication, but for adults is generally 150 to 400 mg daily in divided doses.  Dipyridamole is also available as a solution for injection for use as an alternative to exercise in thallium myocardial perfusion imaging (“dipyridamole stress test”).  Dipyridamole is generally well tolerated, but side effects can include headache, dizziness, flushing, chest pain, gastrointestinal upset, nausea, diarrhea, rash and pruritus.

 

Hepatotoxicity

Dipyridamole has been associated with a low rate of serum enzyme elevations during therapy, but in large clinical trials the frequency of liver enzyme abnormalities was similar with dipyridamole therapy as with placebo.  Cases of clinically apparent acute liver injury from dipyridamole have not been published although hepatitis is listed as a potential side effect in the product label.

 

Drug Class:  Antithrombotic AgentsAntiplatelet Agents

 

Other Drugs in the Subclass, Antiplatelet Agents: AspirinCangrelor, Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine, Vorapaxar

 

Top of page


PRODUCT INFORMATION
Dipyridamole

 

REPRESENTATIVE TRADE NAMES
Dipyridamole – Generic, Persantine®

 

DRUG CLASS
Antithrombotic Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Dipyridamole 211914-51-1 C25-H25-N7-O3 Dipyridamole Chemical Structure

Top of page


REFERENCES
Dipyridamole

 

References updated:  23 July 2013

  1. Zimmerman HJ. Platelet aggregation inhibitors. Drugs used in cardiovascular disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 639-412.  (Textbook of hepatotoxicity published in 1999; mentions that there are no published cases of hepatic injury associated with dipyridamole).

  2. De Marzio DH, Navarro VJ.   Hepatotoxicity of cardiovascular and antidiabetic drugs.  In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 519-40.  (Review of hepatotoxicity of cardiovascular agents including antiplatelet drugs; dipyridamole is not discussed).

  3. Weitz JI.  Antiplatelet drugs.  Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs.  In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 868-72.  (Textbook of pharmacology and therapeutics).

  4. Picano E; PISA(Persantin In Stable Angina) study group. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study. Eur Heart J 2001; 22: 1785-93. PubMed Citation  (Among 400 patients with stable angina treated with dipyridamole vs placebo, headache [25% vs 6%], diarrhea [14% vs 6.5%], and nausea [5.6% vs 1.5%] were more frequent among dipyridamole treated patients; no mention of liver adverse events or ALT levels).

  5. Humphreys DM, Street J, Schumacher H, Bertrand-Hardy JM, Palluk R. Dipyridamole may be used safely in patients with ischaemic heart disease. Int J Clin Pract 2002; 56: 121-7. PubMed Citation  (Review of cardiac adverse events during therapy with dipyridamole indicates no evidence of increased risk).

  6. Babaoglu MO, Karadag O, Saikawa Y, Altundag K, Elkiran T, Yasar U, Bozkurt A. Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report. Eur J Clin Pharmacol 2004; 60: 455-6. PubMed Citation  (52 year old man with acute myeloblastic leukemia in relapse received an induction regimen while also on dipyridamole and developed jaundice with little change in serum enzyme levels, dying a few days later of septicemia; authors suggested a drug-drug interaction between dipyridamole and cytosine arabinoside).

  7. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin(ESPRIT): randomised controlled trial. Lancet 2006; 367(9523): 1665-73. PubMed Citation  (Among 2739 patients treated with dipyridamole/aspirin or aspirin alone after mild stroke or transient ischemic attack, headache was major reason for discontinuation of dipyridamole; no mention of liver adverse events).

  8. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, et al.; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51. PubMed Citation  (Controlled trial of dipyridamole/aspirin vs clopidogrel in 20,332 patients with history of stroke followed for an average of 2.5 years; hepatobiliary adverse events occurred in 0.8% on dipyridamole/aspirin vs 0.9% on clopidogrel, but did not account for any of the early discontinuations or deaths).

  9. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network(DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. PubMed Citation  (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, none were attributed to antiplatelet agents).

  10. Previtera AM, Pagani R. Agranulocytosis and hepatic toxicity with ticlopidine therapy: a case report. J Med Case Reports 2010; 4: 269. PubMed Citation  (70 year old woman developed agranulocytosis [neutrophils 100/L] 4 weeks after starting ticlopidine, with abnormal liver tests [bilirubin normal, ALT 560 U/L, Alk P 821 U/L, GGT 449 U/L], resolving within 4 weeks of stopping [and switching to dipyridamole and aspirin]).

  11. Bath PM, Cotton D, Martin RH, Palesch Y, Yusuf S, Sacco R, Diener HC, et al.; PRoFESS Study Group. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke 2010; 41: 732-8. PubMed Citation  (Among 1360 patients treated with either clopidogrel or dipyridamole/aspirin with 72 hours of a stroke, serious adverse events were low and similar between the two groups; no mention of hepatic adverse events).

Top of page

 

OTHER REFERENCE LINKS
Dipyridamole
  1. PubMed logoRecent References on Dipyridamole

  2. Clinical Trials logoTrials on Dipyridamole

Top of page